Eye care practitioners in Australia have access to a new treatment modality for myopia with the listing of Eyerising International’s Repeated Low-Level Red-Light (RLRL) therapy device by the Australian Therapeutic Goods Administration (ARTG No: 41275).
Based on the work of Professor Mingguang He, a world-renowned ophthalmologist and myopia expert, the technology is indicated for the treatment of myopia at home.
Based on the work of Professor Mingguang He… the technology is indicated for the treatment of myopia at home
The device is already in widespread use overseas across populations including students, with distribution licenses finalised and first sales having occurred in Japan, New Zealand, and Turkey. The company is targeting a minimum roll out in 10 countries by the end of December 2023.
Austrade has actively assisted Eyerising International Pty Ltd in cementing its distribution arrangements and continues to help the worldwide rollout.
To find out more, visit www.eyerisinginternational.com.
